Francisco Gómez-Ulla1, Manuel F Bande2, Maximino Abraldes3. 1. Instituto Oftalmológico Gómez-Ulla, Calle Maruxa Mallo 3, 15706, Santiago de Compostela, Spain. franciscogomez-ulla@institutogomez-ulla.es. 2. Expert Retina Training Program, Hospital Provincial de Conxo, Santiago de Compostela, Spain. verman017@hotmail.com. 3. Instituto Oftalmológico Gómez-Ulla, Calle Maruxa Mallo 3, 15706, Santiago de Compostela, Spain. maxiabraldes@gmail.com.
Abstract
INTRODUCTION: Ocriplasmin is a human plasmin fragment indicated for vitreomacular traction treatment. With its increasing use, several reported cases have suggested possible toxicity to the retina. CASE: We describe a case of a 55-year-old woman with symptomatic vitreomacular traction and a macular hole in the right eye who showed an acute decrease in visual acuity after an intravitreal ocriplasmin injection. Spectral-domain optical coherence tomography showed an alteration in the ellipsoid layer. Significant retinal vessel constriction was observed by angiography. The visual acuity improved to 20/100, and the electroretinogram progressively improved after the 1-year follow-up and following pars plana vitrectomy. CONCLUSIONS: A decrease in visual acuity and an enlargement of the macular hole were observed while studying this patient. This study shows the recovery of adverse effects caused by intravitreal injection of ocriplasmin for 1-year follow-up.
INTRODUCTION: Ocriplasmin is a humanplasmin fragment indicated for vitreomacular traction treatment. With its increasing use, several reported cases have suggested possible toxicity to the retina. CASE: We describe a case of a 55-year-old woman with symptomatic vitreomacular traction and a macular hole in the right eye who showed an acute decrease in visual acuity after an intravitreal ocriplasmin injection. Spectral-domain optical coherence tomography showed an alteration in the ellipsoid layer. Significant retinal vessel constriction was observed by angiography. The visual acuity improved to 20/100, and the electroretinogram progressively improved after the 1-year follow-up and following pars plana vitrectomy. CONCLUSIONS: A decrease in visual acuity and an enlargement of the macular hole were observed while studying this patient. This study shows the recovery of adverse effects caused by intravitreal injection of ocriplasmin for 1-year follow-up.
Authors: Michael Bach; Mitchell G Brigell; Marko Hawlina; Graham E Holder; Mary A Johnson; Daphne L McCulloch; Thomas Meigen; Suresh Viswanathan Journal: Doc Ophthalmol Date: 2012-10-17 Impact factor: 2.379
Authors: Donald C Hood; Michael Bach; Mitchell Brigell; David Keating; Mineo Kondo; Jonathan S Lyons; Michael F Marmor; Daphne L McCulloch; Anja M Palmowski-Wolfe Journal: Doc Ophthalmol Date: 2011-10-30 Impact factor: 2.379
Authors: David G Birch; Matthew S Benz; Daniel M Miller; Andrew N Antoszyk; Joseph Markoff; Petra Kozma; Esmeralda Meunier; Robert C Sergott Journal: Retina Date: 2018-02 Impact factor: 4.256